Skip to Navigation Skip to Content Skip to Footer

Microbiology Logo Microbiology & Immunology
Te Tari Moromoroiti me te Ārai Mate


  1. Laws, G. A., Kemp, R. A., Probiotics and health: understanding probiotic trials, New Zealand Medical Journal, 2019. Vol 132 No 1498.
  2. Norton, S. E*.,Ward-Hartstonge,K. A*.McCall, J. L., Leman, J. K. H.,Taylor, E. H.,Munro, F., Black, M. A.,Fazekas de St. Groth, B., McGuire,H. M. andKemp, R. (2019)A. High-Dimensional Mass Cytometric Analysis Reveals an Increase in Effector Regulatory T Cells as a Distinguishing Feature of Colorectal Tumors. Journal of immunology, available online February 6th2019.
  3. Leman JKH, Sandford SK, Rhodes JL, Kemp RA. Multiparametric analysis of colorectal cancer immune responses. 2018. World J Gastroenterol. Jul 21;24(27):2995-3005. doi: 10.3748/wjg.v24.i27.2995
  4. Ailin Lepletier, Viviana P Lutzky, Deepak Mittal, Kimberley Stannard, Thomas S Watkins, Champa N Ratnatunga, Corey Smith, Helen M McGuire, Roslyn A Kemp, Pamela Mukhopadhyay, Nicola Waddell, Mark J Smyth, William C Dougall, John J Miles. The immune checkpoint CD96 defines a distinct lymphocyte phenotype & is highly expressed on tumor‐infiltrating T cells. 2018. Immunol Cell Biol. First published: 17 September 2018.
  5. Norton S, Kemp R, Computational Analysis of High Dimensional Mass Cytometry Data from Clinical Tissue Samples. Methods Mol Biol. 2018;1770 (In Press)
  6. Taylor ES, McCall JL, Shen S, Girardin A, Munro F, Black MA, Ward-Hartstonge KA, Kemp RA. Prognostic roles for IL-2-producing and CD69+ T cell subsets in colorectal cancer patients. Int J Cancer2018 Oct 15;143(8):2008-2016. doi: 10.1002/ijc.31598
  7. Ward-Hartstonge KA and Kemp RA. Regulatory T-cell heterogeneity and the cancer immune response.  Clinical & Translational Immunology (2017) 6, e154; doi:10.1038/cti.2017.43 Published online 15 September 2017
  8. Ward-Hartstonge, K.A., McCall, J.L., McCulloch, T.R. et al.  Inclusion of BLIMP-1+ effector regulatory T cells improves the Immunoscore in a cohort of New Zealand colorectal cancer patients - a pilot studyCancer Immunol Immunother (2017) 66: 515.
  9. Neumann S, Shirley SA, Kemp RA, Hook SM. Improved anti-tumour activity of a therapeutic melanoma vaccine through the use of the dual COX-2/5-LO inhibitor licofelone. Frontiers in Immunology. In Press
  10. Highton AJ, Girardin A, Bell GM, Hook SM, Kemp RA. Chitosan gel vaccine protects against tumour growth in an intracaecal mouse model of cancer by modulating systemic immune responses. BMC Immunol.  DOI 10.1186/s12865-016-0178-4
  11. Taylor ES, McCall JL, Girardin A, Munro FM, Black MA, Kemp RA. Functional impairment of infiltrating T cells in human colorectal cancer. Oncoimmunol. In Press DOI 10.1080/2162402X.2016.1234573
  12. Parayath NN, Nehoff H, Norton SE, Highton AJ, Taurin S, Kemp RA, Greish K. Styrene maleic acid encapsulated paclitaxel micelles: anti-tumour activity and toxicity studies following oral administration in a murine orthotopic colon cancer model. Int J Nanomedicine. 2016 :11 3979-91
  13. Norton SE, Dunn ETJ, McCall JL, Munro F, Kemp RA. Gut macrophage phenotype is dependent on the tumor microenvironment in colorectal cancer. Clinical Transl Med. 2016. 5, e76; doi: 10.1038/cti.2016.21
  14. Dunn ETJ, Taylor ES, Stebbings S, Schultz M, Butt AG, Kemp RA. Distinct immune signatures in the colon of Crohn's disease and Ankylosing spondylitis patients in the absence of inflammation.  Immunol Cell Biol. 2015 Dec 9. doi: 10.1038/icb.2015.112. [Epub ahead of print]
  15. Norton S, Ward-Hartstonge K, Taylor E, Kemp RA. Immune cell interplay in colorectal cancer prognosis. Review. WJGO. 2015. Oct 15;7(10):221-32. doi: 10.4251/wjgo.v7.i10.221.
  16. Highton AJ, Korjarunchitt, Girardin A, Hook S, Kemp RA. Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma. Immunol. Cell Biol. 2015 Aug;93(7):634-40. doi: 10.1038/icb.2015.14
  17. Highton AJ and Kemp RA. Immunological Background. In Subunit Vaccines, Springer 2015.
  18. Neumann S, Burket K, Kemp R, Rades T, Dunbar PR, Hook S. Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants. Immunol. Cell Biol. 2014 92(6):535-42
  19. Kemp RA, Dunn E, Schultz M.  Immunomodulators in Inflammatory Bowel Disease: an emerging role for biologic agents.  BioDrugs 2013 27(6):585-90
  20. Girardin A, McCall J, Black MA, Edwards F, Phillips V, Taylor ES, Reeve AE, Kemp RA. Inflammatory and regulatory T cells contribute to a unique immune microenvironment in tumor tissue of colorectal cancer patients.  Int J Cancer 2013 132(8):1842-50.
  21. Gordon S, Young K, Wilson R, Rizwan S, Kemp R, Rades T, Hook S.  Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems.  J Liposome Res 2012 22(3):193-204
  22. Kemp RA, Black MA, McCall J, Yoon HS, Phillips V, Anjomshoaa A, Reeve AE.  T cell subpopulations in lymph nodes may not be predictive of patient outcome in colorectal cancer. J Exp Clin Cancer Res 2011 30(1):78
  23. Ting YT, Coates PT, Marti HP, Dunn AC, Parker RM, Pickering JW, Jack RW, Kemp RA, Walker RJ, McLellan AD. Urinary soluble HLA-DR is a ?potential biomarker for acute renal transplant rejectionTransplantation 2010 89(9):1071.
  24. Kemp RA, Pearson CF, Cornish GH, Seddon BP. Evidence of STAT5 dependent and independent routes to CD8 memory formation and a preferential role for IL-7 over IL-15 in STAT5 activation. Imm. Cell. Biol. 2010 88(2):213.
  25. Bouwer AL, Netter P, Kemp RA, McLellan AD. A defined serum-free medium useful for monitoring anti-melanoma responses induced by dendritic cell immunotherapy. J. Immunol. Methods. 2010.  352(1-2):178.
  26. Kemp RA, Yoon HS, Anjomshoaa A, Reeve AE.  Using T cell responses in the lymph node to predict patient outcome in colorectal cancer. J. Immunol. 2009. 182:40.16
  27. Kemp RA, Backstrom BT, Ronchese F. The phenotype of Type 1 and Type 2 CD8+ T cells activated in vitro is affected by culture conditions and correlates with effector activityImmunol. 2005 Jul; 115(3) 315-24.
  28. Jelley-Gibbs DM, Dibble JP, Filipson S, Haynes L, Kemp RA, Swain SL. Repeated stimulation of CD4 effector T cells can limit their protective functionJ Exp Med. 2005 Apr; 210(7):1101-12.
  29. Powell TJ, Brown DM, Hollenbaugh JA, Charbonneau T, Kemp RA, Swain SL, Dutton RW. CD8+ T cells responding to influenza infection reach and persist at higher numbers than CD4+ T cells independently of precursor frequencyClin Immunol. 2004 Oct;113(1):89-100.
  30. Kemp RA, Powell TJ, Dwyer DW, Dutton RW. Cutting edge: regulation of CD8+ T cell effector population sizeJ Immunol. 2004 Sep 1;173(5):2923-7.
  31. Begg, D, Kemp R, Griffin JFT. Normal levels of immunocompetence in possums (Trichosurus vulpecula) exposed to different laboratory housing conditions post captureImmunol Cell Biol. 2004 Jun;82(3):253-6.
  32. Kemp RA, Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunityJ Immunol. 2001 Dec 1;167(11):6497-502.
  33. *Chtanova T, *Kemp RA, Sutherland AP, Ronchese F, Mackay CR. Gene microarrays reveal extensive differential gene expression in both CD4(+) and CD8(+) type 1 and type 2 T cells. J Immunol. 2001 Sep 15;167(6):3057-63. * contributed equally
  34. Ritchie DS, Hermans IF, Lumsden JM, Scanga CB, Roberts JM, Yang J, Kemp RA, Ronchese F. Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivoJ Immunol Methods. 2000 Dec 1;246(1-2):109-17